Piperidinyltetralin sigma ligands.

J Med Chem

DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0353.

Published: February 1994

Sigma receptor ligands have been proposed to be potential antipsychotic drugs based on their activity profile in animal behavioral models and their indirect modulation of dopaminergic function. Compound 15 (DuP 734) is a combined antagonist of sigma-1 and serotonin 5HT2 receptors, which has been entered into phase I clinical trials as a potential antipsychotic drug. Tetralins 1 and 2 were prepared to determine whether restriction of the conformation of 15 and its analogs may lead to differences in binding selectivity or in vivo profile. The syntheses and the structure-activity relationships of these compounds are reported herein. A reduced derivative, 14, had high affinity for sigma-1 and serotonin 5HT2 receptors as well as excellent oral activity in some animal antipsychotic models. Furthermore, compound 14 failed to cause catalepsy in the rat up to 90 mg/kg (po).

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm00029a008DOI Listing

Publication Analysis

Top Keywords

potential antipsychotic
8
sigma-1 serotonin
8
serotonin 5ht2
8
5ht2 receptors
8
piperidinyltetralin sigma
4
sigma ligands
4
ligands sigma
4
sigma receptor
4
receptor ligands
4
ligands proposed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!